These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28832268)

  • 1. DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma.
    Rello-Varona S; Tirado OM
    Pharmacogenomics; 2017 Sep; 18(14):1307-1309. PubMed ID: 28832268
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospects and challenges for the development of new therapies for Ewing sarcoma.
    Grohar PJ; Helman LJ
    Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat-A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report.
    van Maldegem AM; Bovée JV; Gelderblom H
    Pediatr Blood Cancer; 2016 Oct; 63(10):1840-3. PubMed ID: 27245095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic drugs take on cancer.
    Kaiser J
    Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract]   [Full Text] [Related]  

  • 6. Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation.
    Ryland KE; Hawkins AG; Weisenberger DJ; Punj V; Borinstein SC; Laird PW; Martens JR; Lawlor ER
    Mol Cancer Res; 2016 Jan; 14(1):26-34. PubMed ID: 26573141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
    Jedlicka P
    Expert Opin Ther Targets; 2017 Nov; 21(11):997-999. PubMed ID: 29022407
    [No Abstract]   [Full Text] [Related]  

  • 9. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
    Welch D; Kahen E; Fridley B; Brohl AS; Cubitt CL; Reed DR
    PLoS One; 2019; 14(9):e0222228. PubMed ID: 31550266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies for advanced Ewing sarcoma family of tumors.
    Jiang Y; Ludwig J; Janku F
    Cancer Treat Rev; 2015 May; 41(5):391-400. PubMed ID: 25869102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the potential of epigenetics in drug development?
    Lundstrom K
    Future Med Chem; 2015; 7(3):239-42. PubMed ID: 25826357
    [No Abstract]   [Full Text] [Related]  

  • 14. Epigenetic therapies reach main street.
    Bates SE
    Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089
    [No Abstract]   [Full Text] [Related]  

  • 15. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising strategies: Combination of epigenetic inhibitors for cancer therapy.
    Gronemeyer H
    Int J Cancer; 2020 Nov; 147(10):2656-2657. PubMed ID: 32599650
    [No Abstract]   [Full Text] [Related]  

  • 17. Epigenetic therapies, still in the midway between facts and fiction.
    Sánchez-Pernaute O
    Reumatol Clin; 2017; 13(6):311-312. PubMed ID: 28571731
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma.
    Nestheide S; Bridge JA; Barnes M; Frayer R; Sumegi J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1437-46. PubMed ID: 23508900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of novel epigenetic molecular-targeting agents].
    Sowa Y; Sakai T
    Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.
    Sampson VB; Kamara DF; Kolb EA
    Expert Opin Drug Discov; 2013 Oct; 8(10):1181-9. PubMed ID: 23844615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.